Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “pd-”

81 pharma patents match "pd-" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 81
Index total 30,257
Page 2 / 4

Quick answer

This filtered view shows 81 pharmaceutical patents matching "pd-" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

81 results for “pd-” · 30,257 patents in full index Clear search

  1. US 11976128

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Granted May 7, 2024 · Expires May 2, 2044

    granted
  2. US 11939581

    Methods and compositions for targeting PD-L1

    Aligos Therapeutics, Inc. · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  3. US 11932692

    Methods of treating cancer pain by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 19, 2024 · Expires Mar 14, 2044

    granted
  4. US 11926668

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 12, 2024 · Expires Mar 7, 2044

    granted
  5. CA 3259391

    POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1

    ABBVIE BIOTHERAPEUTICS INC [US] · Granted Feb 1, 2024 · Expires Jan 27, 2044

    granted
  6. US 11786553

    Chimeric cytokine receptors bearing a PD-1 ectodomain

    Allogene Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  7. US 11760761

    Methods and compositions for targeting PD-L1

    Aligos Therapeutics, Inc. · Granted Sep 19, 2023 · Expires Sep 14, 2043

    granted
  8. US 11760764

    Methods and compositions for targeting PD-L1

    Aligos Therapeutics, Inc. · Granted Sep 19, 2023 · Expires Sep 14, 2043

    granted
  9. CA 3245150

    COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE

    TRISHULA THERAPEUTICS INC [US] · Granted Sep 7, 2023 · Expires Sep 2, 2043

    granted
  10. US 11746152

    Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1

    The Board of Regents of the University of Texas System · Granted Sep 5, 2023 · Expires Aug 31, 2043

    granted
  11. US 11718679

    CD137 antibodies and PD-1 antagonists and uses thereof

    Compass Therapeutics LLC · Granted Aug 8, 2023 · Expires Aug 3, 2043

    granted
  12. US 11713353

    Single-domain antibodies and variants thereof against PD-1

    Nanjing Legend Biotech Co., Ltd · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted
  13. US 11685918

    Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  14. US 11685775

    Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody

    The Regents of the University of California · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  15. US 11673954

    Single-domain antibodies and variants thereof against PD-L1

    Nanjing Legend Biotech Co., Ltd · Granted Jun 13, 2023 · Expires Jun 8, 2043

    granted
  16. US 11660352

    Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof

    The Board of Regents of the University of Texas System · Granted May 30, 2023 · Expires May 25, 2043

    granted
  17. US 11661455

    Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety

    Orionis Biosciences, Inc · Granted May 30, 2023 · Expires May 25, 2043

    granted
  18. US 11566076

    Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

    Five Prime Therapeutics, Inc. · Granted Jan 31, 2023 · Expires Jan 26, 2043

    granted
  19. US 11542312

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Jan 3, 2023 · Expires Dec 29, 2042

    granted
  20. US 11525002

    Human PD-L1 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted
  21. US 11505600

    Methods of treating skin cancer by administering a PD-1 inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted
  22. US 11498966

    PD-1 and PD-L1 binding agents

    Orionis Biosciences, Inc · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  23. US 11497734

    Dual inhibitors of TIM-3 and PD-1 pathways

    Aurigene Discovery Technologies Limited · Granted Nov 15, 2022 · Expires Nov 10, 2042

    granted
  24. US 11464795

    Saponin compound targeting PD-1 and application thereof

    East China University of Science and Technology · Granted Oct 11, 2022 · Expires Oct 6, 2042

    granted